Company: Aurobindo Pharma Ltd

Injectables, orals to be rolled out by the end of FY20
Aug. 23, 2019, 10:03 p.m.

Aurobindo Pharma Ltd’s consolidated net profit increased 39.5 per cent at Rs 636 crore in the first quarter ended June 30, 2019, compared with Rs 456
Aug. 8, 2019, 10:30 a.m.

Consolidated total revenue from operations rose to ₹5,444.60 crore for the quarter.Europe formulations revenue stood at ₹1,391.6 crore, up 16.1% year-on-year
Aug. 7, 2019, 9:25 p.m.

Revenue from operations rose 28.1% year-on-year to Rs 5,444.6 crore during the quarter under review
Aug. 7, 2019, 8:22 p.m.

Aurobindo had reported Rs 19,563.6 crore in revenues in FY19 with an year-on-year growth of 18.5 per cent
Aug. 6, 2019, 3:34 p.m.

US Federal Trade Commission is yet to clear the deal announced last year.In 2018, Aurobindo announced it will buy Sandoz’s commercial operations for $900 million
July 30, 2019, 11:56 p.m.

Cinacalcet Hydrochloride tablets had an annual sale of ~US$1,449mn for the 12 months ending May 2019, as per IQVIA.
July 11, 2019, 9:21 a.m.

Check out the companies which will be in focus during trade today based on recent and latest news developments.
July 11, 2019, 7:59 a.m.

Firm may have a tough task ahead improving manufacturing practices across the board through remediation running into months and years
July 4, 2019, 5:21 p.m.

The FDA recently issued a warning letter to the firm after inspecting its active pharmaceutical ingredient facility (Unit XI) in Andhra Pradeshs Srikakulam district and stated that CGMP observations were similar in nature as those made at other facilities.
July 4, 2019, 9:30 a.m.